Alternate Endpoints for Phase II Trials in Advanced Neuroendocrine Tumors

BACKGROUND. In phase II trials for neuroendocrine tumors (NETs), the objective response rate (ORR) is traditionally used as a primary endpoint. However, the validity of the ORR as a primary endpoint has never been systematically examined. Therefore, a literature‐based analysis of phase II trials for...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Oncologist
Egile Nagusiak: Imaoka, Hiroshi, Sasaki, Mitsuhito, Takahashi, Hideaki, Hashimoto, Yusuke, Ohno, Izumi, Mitsunaga, Shuichi, Watanabe, Kazuo, Umemoto, Kumiko, Kimura, Gen, Suzuki, Yuko, Kan, Motoyasu, Ikeda, Masafumi
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: AlphaMed Press 2018
Gaiak:
Endocrinology
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC6324626/
https://ncbi.nlm.nih.gov/pubmed/30072388
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2017-0651
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak